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SUMMARY This study was designed to clarify the association between inter-episode bipolar
disorder (BD) and sleep architecture. Participants completed a baseline symptom and
sleep assessment and, 3 months later, an assessment of symptoms and impairment. The
effects of psychiatric medications on sleep architecture were also considered. Partic-
ipants included 22 adults with BD I or II (inter-episode) and 22 non-psychiatric
controls. The sleep assessment was conducted at the Sleep and Psychological Disorders
Laboratory at the University of California, Berkeley. Follow-up assessments 3 months
later were conducted over the phone. Results indicate that, at the sleep assessment, BD
participants exhibited greater rapid eye movement sleep (REM) density than control
participants with no other group differences in sleep architecture. Sleep architecture was
not correlated with concurrent mood symptoms in either group. In the BD group,
duration of the first REM period and slow-wave sleep (SWS) amount were positively
correlated with manic symptoms and impairment at 3 months, while REM density was
positively correlated with depressive symptoms and impairment at 3 months. The
amount of Stage 2 sleep was negatively correlated with manic symptoms and
impairment at 3 months. In contrast, for the control group, REM density was
negatively correlated with impairment at 3 months. SWS and Stage 2 sleep were not
correlated with symptoms or impairment. Study findings suggest that inter-episode
REM sleep, SWS and Stage 2 sleep are correlated with future manic and depressive
symptoms and impairment in BD. This is consistent with the proposition that sleep
architecture may be a mechanism of illness maintenance in BD.
k e y w o r d s bipolar disorder, rapid eye movement sleep, sleep architecture, slow-
wave sleep, stage 2 sleep
INTRODUCTION
Individuals with bipolar disorder (BD) spend approximately
50% of their adult lives unwell, with the majority of this time
marked by subsyndromal symptoms persisting into the inter-
episode period (Judd et al., 2002). Sleep disturbance in the
inter-episode period has been reported to be comparable to
chronic insomnia and to have a prognostic value in BD (see
Harvey, 2008 for review). For instance, decreased sleep has
been found to be the most common prodrome of mania
(Jackson et al., 2003) and to predict depressive symptoms at a
6-month follow-up (Perlman et al., 2006). Hence, the present
study focused on inter-episode sleep disturbance as a mecha-
nism that may contribute to impairment and be associated
with future illness course. To the best of our knowledge,
studies utilizing sleep disturbance as a predictor of symptoms
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and impairment in BD have relied on subjective perceptions of
sleep (e.g. Perlman et al., 2006) or have experimentally induced
sleep deprivation in the lab and observed next-day effects
(Wehr et al., 1987). We aimed to extend past findings by
evaluating the predictive value of objectively measured sleep
architecture in inter-episode BD.
Increased rapid eye movement (REM) activity (i.e. short-
ened REM latency, longer duration of the first REM period,
higher percentage of REM over the course of the night and
greater REM density) has been widely reported in unipolar
depression (e.g. Benca et al., 1992), and REM sleep has been
proposed to have a mood-regulatory role that malfunctions
in mood disorders (Cartwright et al., 1998). REM in BD has
received less empirical attention than in unipolar depression,
and the evidence is mixed. Patients with BD who are manic
or depressed have been reported to exhibit decreased (e.g.
Hudson et al., 1992), increased (e.g. Giles et al., 1986) or
equivalent REM latencies (Jernajczyk, 1986) relative to
healthy controls and to patients diagnosed with unipolar
depression. In the inter-episode period, patients with BD
have shown sleep marked by increased REM activity
(Knowles et al., 1986) and sleep that does not differ from
that of controls (Sitaram et al., 1982). Studies of healthy
relatives of individuals diagnosed with a mood disorder point
to the possibility that disturbances in REM sleep may be a
marker of affective disorder vulnerability. Such studies
suggest that the sleep of relatives of individuals diagnosed
with unipolar depression or BD is marked by increased REM
activity compared with controls (Giles et al., 1998; Modell
et al., 2003). In addition, greater REM density has been
found to distinguish those relatives who go on to experience
an affective episode from unaffected relatives and controls
(Modell et al., 2007).
Slow-wave sleep (SWS), which consists of Stages 3 and 4, is
thought to have a restorative function in healthy individuals
that includes memory consolidation and cell regeneration, and
has been found to be decreased in unipolar depression (e.g.
Benca et al., 1992). The two-process model of sleep regulation
proposes that SWS is an index of the homeostatic process
(Borbely, 1982), which may be weakened in depression
(Borbely, 1987). Decreased SWS has also been reported in
BD (Jovanovic, 1977) and in depressed adolescents who go on
to have a BD illness course (Rao et al., 2002). However, most
studies report SWS in mania and BD to be equivalent to that
of healthy controls (Hudson et al., 1988, 1992; Jernajczyk,
1986; Mendelson et al., 1987). Thus, the manner in which SWS
is disturbed in BD is unclear, particularly during the inter-
episode period.
Stage 2 sleep is also thought to have an important
restorative and sleep-protective function (De Gennaro and
Ferrara, 2003; Hayashi et al., 2005). Although it is understud-
ied in mood disorders, decreased Stage 2 sleep has been found
in both unipolar and BD (de Maertelaer et al., 1987).
Additionally, in studies of clozapine, treatment response in
BD was most dramatically associated with the enhancement of
Stage 2 sleep (Hinze-Selch et al., 1997).
The present study was designed to clarify the association
between BD and REM, SWS and Stage 2 sleep. We aimed to
investigate whether there is a cross-sectional association
between symptoms and sleep architecture, and whether sleep
architecture predicts symptoms and mood-associated impair-
ment at 3-month follow-up in patients with BD during the
inter-episode period relative to a non-psychiatric control
group. Our first hypothesis was that higher levels of depressive
and manic symptoms at the baseline sleep assessment would be
associated with increased REM activity (shorter REM latency,
higher REM%, longer duration of first REM, greater REM
density), and that increased REM activity would be associated
with higher levels of depressive symptoms, manic symptoms
and impairment at 3-month follow-up. Second, we hypothe-
sized that increased Stage 2 sleep would be associated with
lower levels of manic and depressive symptoms, impairment at
the baseline sleep assessment and at the 3-month follow-up.
Given the mixed findings for SWS reported in the published
reports, we included SWS on an exploratory basis.
Our third study aim relates to medication effects, an issue
that increasingly requires consideration in neuroscience and
psychological research on serious mental illness. A large
majority of patients with BD are treated with polypharmacy
(Ghaemi et al., 2006). Thus, if research is conducted on only
medication-free participants, progress will be slow and the
results may not be generalizable to the majority of patients
with BD. Hence, our third aim was to devise an approach to




Participants were recruited from advertisements and referrals
targeting good sleepers and individuals diagnosed with BD.
Of the 266 callers who were screened, 51 chose not to
participate or could not be reached subsequently, 25 did not
complete the protocol and a total of 146 were excluded from
participating in either the BD or the control group. Partici-
pants were excluded from the BD group for: not being under
psychiatric care (requirement of the ethics committee; n = 23);
not meeting Structured Clinical Interview for DSM-IV (SCID-
IV; First et al., 1994) diagnostic criteria for BD Type I or II
(n = 22); and diagnosis of a current substance or alcohol
abuse disorder (n = 4). In addition, participants were
excluded from the BD group for not being inter-episode, as
defined by: a score greater than 11 on the Clinician Rated
Inventory of Depressive Symptomatology (IDS-C; Rush et al.,
1996); a score greater than 7 on the Young Mania Rating Scale
(YMRS; Young et al., 1978); or meeting SCID-IV criteria for
current depressive, manic or hypomanic episode (n = 17).
Participants were excluded from participating in the control
group for: lifetime history of Axis I disorder according to the
SCID-IV (n = 33); subjective sleep complaints according to
the Duke Structured Interview for Sleep Disorders (DSISD;
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Edinger et al., 2004; n = 24); and reported first-degree
relatives with a diagnosis of BD or schizophrenia (n = 6).
Participants were excluded from either group if they had a
severe medical illness (e.g. autoimmune disorder, cancer;
n = 7) or a confounding sleep disorder (e.g. sleep apnea,
restless leg syndrome), based on their responses to the DSISD
or based on Respiratory Distress Index (RDI) greater than 5
or Periodic Limb Movement (PLM) index greater than 15
found over the course of 1 night of polysomnography (PSG)
screening in the lab (n = 17).
The demographics of the BD group (n = 22) and control
group (n = 22) are presented in Table 1. There were no
significant differences between the two groups. Participants
ranged in age from 20 to 61 years, and represented a range of
socioeconomic and ethnic groups. All participants in the BD
group met diagnostic criteria for BD Type I (n = 19) or Type
Table 1 Demographics, sleep architecture variables, symptoms and impairment in the BD and control groups
BD (n = 22)
Control
(n = 22) v2 or t
Demographics
Age (in years) 33.95 (10.09) 39.95 (12.62) 1.74
Sex (% female) 90.9% 77.3% -1.22
Marital status (% partnered) 31.8% 27.2% -0.59
Education (% college graduate) 72.8% 72.7% -0.20
Ethnicity (% white) 77.3% 59.1% -1.17
Employed (%) 72.7% 90.9% -1.55
Co-morbid diagnoses in BD group
Panic disorder 4.5% – –
Agoraphobia 4.5% – –
Social phobia 9.1% – –
Specific phobia 27.3% – –
Obsessive compulsive disorder 11.5% – –
Post-traumatic stress disorder 4.5% – –
Generalized anxiety disorder 9.1% – –
Anorexia nervosa 4.5% – –
Binge eating disorder 4.5% – –
Illness history in BD group
Age at illness onset (years) 18.57 (9.44) – –
Total past manic episodes 8.81 (7.60) – –




Time since last mood
episode (months)
7.21 (11.54) – –
Mood symptoms at diagnostic visit and baseline sleep assessment
YMRS diagnostic visit 3.19 (2.27) 1.80 (2.26) -1.96
IDS-C diagnostic visit 7.35 (3.77) 5.20 (4.86) -1.56
YMRS baseline sleep assessment 2.09 (2.20) 0.55 (1.06) -2.97*
IDS-C baseline sleep assessment 5.55 (5.11) 2.36 (1.79) -2.76*
Sleep architecture at baseline sleep assessment
REM variables
REM latency (min) 114.22 (48.42) 106.30 (54.66) -0.51
REM% 22.42 (9.02) 22.49 (8.03) 0.03
Duration of the 1st REM period (min) 21.80 (17.53) 14.88 (11.10) 1.56
REM density 17.62 (12.29) 10.38 (8.20) -2.30*
NREM variables
Stage 1% 8.20 (6.99) 5.77 (4.46) -1.37
Stage 2% 55.79 (16.10) 53.62 (8.67) -0.55
SWS% 14.06 (10.71) 17.40 (9.46) 1.09
Symptoms and impairment at 3-month follow-up
YMRS (mania) 3.57 (2.62) 1.00 (1.45) -4.03***
IDS-C (depression) 11.65 (9.07) 2.09 (1.82) -4.85***
WSAS (impairment) 13.67 (10.19) 4.41 (5.61) -3.73**
Mean values are presented with standard deviations in parentheses.
BD, bipolar disorder; IDS-C, Clinician Rated Inventory of Depressive Symptomatology; NREM, non-rapid eye movement; REM, rapid eye
movement; SWS, slow-wave sleep; WSAS, Work and Social Adjustment Scale; YMRS, Young Mania Rating Scale.
*P £ 0.05; **P £ 0.005; ***P £ 0.001.
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II (n = 3) according to the SCID-IV, and were determined to
be inter-episode at the first visit based on SCID, IDS-C and
YMRS criteria. Subsequently, the IDS-C and YMRS were
used to determine that the participant was still inter-episode at
all study visits preceding the follow-up. No participants in the
control group were taking psychotropic or hypnotic medica-
tions. However, because the enrollment of a medication-free
BD sample would be unfeasible and unrepresentative, BD
participants were not asked to change or stop taking their
prescribed medications. Thus, 21 of the 22 BD group partic-
ipants were taking psychotropic medications. In addition, as
BD is typically associated with the presence of co-morbid
diagnoses (Kessler et al., 2005), participants were not excluded
on the basis of co-morbid diagnoses other than current alcohol
or substance abuse disorders. Detailed illness history for the
BD group was assessed using the National Institute of Mental
Health retrospective Life-Charting Methodology (NIMH-
LCMr; Leverich and Post, 1993; one participant did not fully
complete the NIMH-LCMr). Data on current co-morbidities
and illness history in the BD group are presented in Table 1.
Procedures
Written informed consent was obtained, and the SCID-IV,
DSISD, NIMH-LCMr, IDS-C, YMRS and demographics and
medication questionnaires were administered at the diagnostic
visit. An acclimation ⁄ screening night was then conducted as a
control for first night effects and to screen for sleep disorders
(e.g. sleep apnea).
The baseline sleep assessment was the second overnight visit,
taking place approximately 1 month following the acclima-
tion ⁄ screening night. Inter-episode status was assessed when
participants arrived using the YMRS and IDS-C. PSG
equipment was then attached. The timing of interviews and
PSG set-up was carefully scheduled in order to allow partic-
ipants to go to bed at their habitual preferred bedtime. A
neutral mood induction was administered immediately prior to
sleep to minimize the potential impact of transient pre-sleep
affective states on sleep architecture. The neutral mood was
induced using a well-validated procedure (Eich et al., 1994),
which combined continuous music and autobiographical recall
techniques. All participants reported being in a neutral mood
prior to sleep, and there were no group differences in mood
prior to (t = -0.50, P > 0.60) or following the mood induc-
tion (t = 0.40, P > 0.60).
The 3-month follow-up assessment took place an average of
82.0 days (SD = 51.4) after the baseline sleep assessment. Itwas
conducted by phone and consisted of theYMRS, IDS-C and the
Work and Social Adjustment Scale (WSAS;Mundt et al., 2002).
Measures
Polysomnography
Polysomnography involves the continuous and simultaneous
recording of electroencephalogram (EEG), electrooculogram
(EOG) and electromyogram (EMG). We used laboratory-
based PSG (Compumedics USA Inc., Charlotte, NC, USA;
Siesta802) that included four EEG leads (C3 ⁄A2, C4 ⁄A1,
O1 ⁄A2, O2 ⁄A1), two EOG leads and two submental EMG
leads. On the acclimation ⁄ screening night, respiratory airflow
(using a nasal and oral thermistor), thoracic and abdominal
displacement, finger pulse oximeter, electrocardiogram (two
EKG leads), and a snoring sensor were added. Data were
scored using the standard Rechtschaffen and Kales criteria for
sleep staging (Rechtschaffen and Kales, 1968). REM latency
corresponds to the time (in minutes) from sleep onset to the
beginning of the first REM period of the night. REM density
was calculated as the percentage of 5-s REM sleep periods that
contained at least one eye movement (Werth et al., 1996).
For the BD group, an average total sleep time of 459.73 min
(SD = 85.50) was available for scoring. This was marginally
significantly longer than the average total sleep time of control
participants, which was 409.52 min (SD = 73.28; t = -2.02,
P = 0.05). Percentages of the various sleep stages were used
instead of total minutes spent in each sleep stage due to group
difference in total sleep time and because participants were not
able to sleep past 09:00 hours because of resource limitations.
Mood symptom measures
The IDS-C (Rush et al., 1996) consists of 30 items, scored on a
0–3 metric, that assess depressive symptom severity for the
preceding week. Scores less than 12 correspond to inter-
episode status meaning no clinical depression is present. The
YMRS (Young et al., 1978) consists of 11 items, scored on a
0–4 metric, that measure the severity of manic symptoms for
the preceding week. Scores less than 8 correspond to inter-
episode status meaning no clinical mania or hypomania is
present. The IDS-C and the YMRS have good psychometric
properties, and are widely used in medical and research
settings (Rush et al., 1996; Young et al., 1978).
Functional impairment measure
The WSAS (Mundt et al., 2002) was used to assess mood-
related functional impairment. This five-item measure has
good internal consistency, test–retest reliability and sensitivity
to disorder severity (Mundt et al., 2002). Individual items are
rated on a 0–8 metric and assess the extent to which the
participants mood causes them to be impaired in occupational
roles, home management, social leisure, private leisure and
relationships.
Data analysis
Independent t-tests and chi-square tests were used to examine
group differences in predictor and outcome variables. To
address the effects of psychotropic medications on sleep
architecture, we employed a multi-step patient-by-patient
approach. anovas were used to test the effect of participants
medication status on sleep architecture. Correlation analyses
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were then used to test our a priori hypotheses. Continuous
symptom and impairment measures were retained as the
outcome measures of interest, as only a small subset of
participants met criteria for hypomania or depression at
follow-up. Where medications appeared to affect sleep archi-
tecture, secondary data analyses of our hypotheses were
conducted in the medication subgroups.
RESULTS
As evident in Table 1, there were no group differences in
symptoms at the diagnostic visit, but the BD group exhibited
more depressive and manic symptoms than the control group
at the baseline sleep assessment. At follow-up, the BD group
had significantly more manic symptoms, depressive symptoms
and functional impairment (based on WSAS total score and
scores for each individual item) than the control group
(Table 1). At follow-up, both manic (t = -2.66, P < 0.05)
and depressive (t = -2.25, P < 0.05) symptoms in the BD
group had increased since the baseline sleep assessment such
that four participants (18.2%) met YMRS criteria for hypo-
mania and 10 (45.5%) met IDS-C criteria for depression. With
respect to sleep architecture, as evident in Table 1, the BD
group had significantly greater REM density than the control
group, though there were no other group differences.
To address medication effects, two of the authors
(P. Eidelman and J. Gruber) independently classified each
medication reported by participants as having no effect, an
enhancing effect or a suppressing effect on REM, SWS and ⁄or
Stage 2 sleep, based on a detailed literature search. In cases
where participants reported taking medications with conflict-
ing sleep effects (e.g. Bupropion is a REM sleep enhancer and
Fluoxetine is a REM sleep suppressor; Ott et al., 2004; Rush
et al., 1998), we reasoned that these effects cancelled each other
out. A list of potential medication effects on the sleep of each
participant was generated by the two authors for 33% of
participants, with a reliability of 100% for those coded by both
authors. As reported in Table 2, anovas and Tukey post hoc
comparisons indicated that participants taking a medication
that suppressed REM had a significantly longer latency to first
REM than participants taking medications with no effect or an
enhancing effect on REM. Participants taking a medication
that suppressed REM also had greater REM density than
participants taking a medication with no effect on REM. There
were no other significant differences in sleep architecture based
on medications (all P > 0.10; Table 2).
Table 3 presents correlations of baseline sleep architecture
with baseline and 3-month follow-up symptoms and impair-
ment. Sleep architecture was not significantly correlated with
concurrent manic and depressive symptoms at the baseline
sleep assessment in either participant group. However, in the
BD group there were four significant correlations (out of 12)
between baseline sleep architecture and follow-up symptoms.
Duration of first REM and SWS% were positively correlated
with manic symptoms, while REM density was positively
correlated with depressive symptoms. Stage 2% was negatively
correlated with manic symptoms. Additionally, there were
three significant correlations (out of six) between sleep archi-
tecture and follow-up impairment in the BD group. REM
density and SWS%were positively correlated with impairment,
while Stage 2% was negatively correlated with impairment. In
the control group, sleep architecture was not significantly
correlated with follow-up symptoms. However, there was one
significant correlation (out of six) for impairment, indicating
that REM density was negatively correlated with impairment in
the control group. Thus, seven significant correlations between
baseline sleep architecture and follow-up symptoms and
impairment emerged in the BD group, while only one signif-
icant correlation was found in the control group.
Correlations between sleep architecture and follow-up
symptoms and impairment were repeated in subgroups of
BD participants based on medication status to examine
potential confounds of medication effects on REM latency
and density. For REM latency all correlations remained
Table 2 Medication effects on sleep architecture in the BD group
Sleep architecture variables
Medication effects
FNo effect on REM (n = 7) Enhance REM (n = 5) Suppress REM (n = 10)
REM latency (min) 94.64 (20.86) 80.96 (45.36) 144.55 (48.27) 5.20*
REM% 23.57 (9.28) 20.95 (11.87) 22.36 (8.23) 0.11
Duration of 1st REM (min) 17.93 (12.55) 19.00 (18.10) 25.90 (20.78) 0.48
REM density 8.81 (5.99) 18.31 (13.83) 23.43 (12.06) 3.67*
No effect on SWS (n = 10) Enhance SWS (n = 12) Suppress SWS (n = 0)
Stage 3% 7.27 (3.93) 9.06 (6.08) – 0.64
Stage 4% 3.37 (3.03) 7.85 (8.36) – 2.60
No effect on Stage 2 (n = 14) Enhance Stage 2 (n = 7) Suppress Stage 2 (n = 1)
Stage 2% 54.62 (17.63) 56.54 (13.04) 65.80 0.23
Mean values are presented with standard deviations in parentheses.
REM, rapid eye movement; SWS, slow-wave sleep.
*P £ 0.05.
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non-significant in both the BD subgroup taking medications
that suppressed REM and the subgroup taking medications
with no ⁄ enhancing effects on REM (all P > 0.10). However,
as evident at the bottom of Table 3, while there were
significant correlations between REM density and follow-up
depressive symptoms and impairment in the BD subgroup
taking medications that suppressed REM, these correlations
were not significant in the subgroup taking medications with
no effect on REM.
DISCUSSION
This study examined the cross-sectional and prospective
associations of sleep architecture and symptoms and impair-
ment in inter-episode BD. At the outset, we recognize that our
discussion needs to be tempered due to the potential effects of
medications on sleep in the BD group. Indeed, a primary aim
of this study was to explore one strategy to manage the
medication effects that need to be considered in neuropsycho-
logical and neurobiological research on BD, so we will return
to this issue throughout the discussion that follows.
The first aim was to cross-sectionally examine the associa-
tion between sleep architecture and symptoms and impairment
in BD relative to non-psychiatric controls. We found no
significant correlations between sleep architecture and concur-
rent symptoms at baseline in either group, although greater
REM density was found in the BD group relative to the
control group. These findings are in contrast to our hypotheses
that REM and Stage 2 sleep would correlate with concurrent
symptoms. One potential explanation may be our requirement
that all participants be inter-episode. By definition, this
restricts the range of depressive and manic symptoms in the
sample, and decreases a likelihood of finding significant
correlations (e.g. Guilford and Fruchter, 1978). A second
potential explanation is that the neutral mood induction
administered prior to sleep may have diffused pre-sleep mood
and canceled out the effects inter-episode symptoms may have
had on sleep architecture. However, the lack of significant
group differences in mood prior to, and following, the neutral
mood induction renders this account unlikely. Our finding of
greater REM density in the BD group relative to controls is
consistent with reports of increased REM activity in inter-
episode BD (e.g. Knowles et al., 1986) and in relatives of
individuals with affective illness (e.g. Modell et al., 2003),
raising the possibility that increased REM density is a
persistent sleep disturbance in BD. Given that we also found
that participants who reported taking REM-suppressing
medications demonstrated greater REM density, this group
difference may also be attributable to medication effects. We
will return to this possibility below.
The second study aim was to prospectively examine
correlations between baseline sleep architecture and future






















BD group (n = 22)
REM variables
REM latency )0.06 )0.35 0.22 )0.12 0.04
REM% )0.05 )0.09 0.16 0.23 0.20
Duration of 1st REM )0.01 )0.32 0.48* 0.23 0.32
REM density )0.11 )0.31 0.12 0.56** 0.54**
NREM variables
Stage 2% )0.13 )0.29 )0.47* )0.15 )0.48*
SWS% 0.21 0.35 0.46* 0.23 0.47*
Control group (n = 22)
REM variables
REM latency )0.12 )0.11 )0.39 )0.33 )0.19
REM% 0.23 )0.12 0.15 0.13 0.36
Duration of 1st REM )0.18 )0.22 )0.01 )0.12 )0.22
REM density )0.34 )0.32 )0.06 0.29 )0.46*
NREM variables
Stage 2% )0.16 0.15 0.28 )0.02 0.04
SWS% )0.52 0.23 0.00 0.24 0.04
Secondary analyses in BD medication subgroups for REM density
REM suppressing (n = 10) – – 0.11 0.72* 0.75*
No effect on REM (n = 7) – – )0.33 )0.04 0.07
SWS%, sum of Stage 3% and Stage 4%; BD, bipolar disorder; IDS-C, Clinician Rated Inventory of Depressive Symptomatology; NREM, non-
rapid eye movement; REM, rapid eye movement; SWS, slow-wave sleep; WSAS, Work and Social Adjustment Scale; YMRS, Young Mania
Rating Scale.
*P £ 0.05; **P £ 0.01.
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symptoms and impairment in BD. A number of significant
findings emerged. Taking REM first, several significant corre-
lations supported the hypothesis that increased REM activity
would be associated with increased symptoms and impairment
at follow-up in the BD group. Specifically, in the BD group
longer duration of first REM was associated with more manic
symptoms at the 3-month follow-up, while greater REM
density was associated with more depressive symptoms and
impairment at the 3-month follow-up. Thus, duration of first
REM and REM density may have predictive value in inter-
episode BD. The negative correlation between REM density
and impairment in the control group, along with the findings
that REM density is positively correlated with impairment and
depression in the BD group, is consistent with the suggestion
that REM serves a mood-regulatory role that is adaptive in
non-psychiatric individuals but malfunctions in mood disor-
ders (e.g. Knowles et al., 1986).
Several findings also supported the hypothesis that greater
amounts of Stage 2 sleep would be associated with less follow-
up symptoms and impairment in the BD group. Specifically,
greater Stage 2% was associated with lower levels of manic
symptoms and impairment in the BD group at follow-up. This
is consistent with theories that Stage 2 sleep fulfills an
important restorative function (Hayashi et al., 2005).
Although Stage 2 sleep has received comparatively little
attention in mood disorder research to date, our findings raise
the possibility that Stage 2 sleep may have some protective
value. Studies demonstrating positive associations between
treatment response and increased Stage 2 sleep in BD (e.g.
Hinze-Selch et al., 1997) are also suggestive of the importance
of Stage 2 sleep.
Given the mixed findings in the literature to date, we did not
make specific hypotheses regarding SWS, including it in our
analyses on an exploratory basis. Results indicated that greater
SWS% predicted more manic symptoms and impairment in
the BD group at the 3-month follow-up. This was somewhat
surprising, given that past research has suggested that
increased levels of SWS appear necessary to normalize
depressed mood (e.g. Borbely, 1982; Jovanovic, 1977). There
are several possible explanations for our findings. First, in
consideration with findings that greater Stage 2% was asso-
ciated with less manic symptoms and impairment at the follow-
up, it is important to note that the durations of Stage 2 sleep
and SWS may change in proportion to each other. Indeed,
while it appears that disturbances in REM and non-rapid eye
movement (NREM) sleep are not reciprocal (Armitage, 2007),
changes in the different stages of NREM sleep are likely to
impact other NREM sleep stages. Second, perhaps even prior
to the baseline assessment, the participants who later devel-
oped manic symptoms were starting to increase their physical
activity. Even a slight increase in exercise and physical activity
is known to increase SWS (Naylor et al., 2000). Third,
participants who later developed manic symptoms may have
already been displaying reduced sleep need prior to the
baseline sleep assessment and were, therefore, becoming sleep
deprived. Based on the two-process model of sleep regulation
and sleep deprivation studies, increased wakefulness is asso-
ciated with greater SWS over the course of the night (e.g.
Borbely, 1982; Brunner et al., 1993). Fourth, perhaps there are
bi-directional effects. Specifically, perhaps greater SWS may be
detrimental in BD, overcompensating for the need to regular-
ize depressed mood and inducing a shift to the opposite end of
the mood spectrum toward manic symptoms.
Our third aim was to address the role of psychotropic
medications. To address potentially confounding effects of
medications in our analyses, we employed a multi-step
approach based on a detailed patient-by-patient literature
review of medication sleep architecture effects. By applying
this approach, in lieu of requesting that all participants be
medication free prior to participating, we reasoned that we
would be able to recruit a participant sample that is more
representative of the larger population of adults with BD. In
the present study, the main concern was the association of
REM-suppressing medications with greater REM density. It is
possible that this medication effect confounded correlations
between REM density and symptoms and impairment at
3 months in the BD group. If this is the case, this medication-
related finding raises a number of possibilities. First, BD
individuals who are prone to depression may also be more
likely to respond to REM-suppressing medications. Second,
REM-suppressing medications may render individuals more
susceptible to depression and impairment, although this seems
unlikely as neither follow-up depressive symptoms (t = -1.74,
P > 0.10) nor impairment (t = -1.70, P > 0.10) were greater
in participants taking REM-suppressing medications than in
participants taking medications with no REM effects. Third,
REM-suppressing medications may affect the mood-regula-
tory function of REM, thereby intensifying the association of
REM density with future depression and impairment. Thus,
further research on REM sleep in BD is needed to clarify the
relationship between medication effects, REM density and
depressive symptoms.
There were several key lessons learned from our approach to
medications that should be addressed in future studies of BD.
First, we recognize that some of the medication subgroups
were small (e.g. only one participant was taking a medication
that suppresses Stage 2 sleep). Thus, some statistical tests were
underpowered to detect meaningful group differences in sleep
architecture based on medication regimen. Future studies with
larger samples could address medication confounds by utiliz-
ing medication subgroups as covariates in statistical analyses.
Second, medication usage should be assessed at follow-up to
check if a medication change or discontinuation may have
occurred, potentially influencing the associations observed
between sleep architecture and follow-up symptoms and
impairment. Third, we reasoned that sleep architecture effects
of medications that enhanced and suppressed the same sleep
stage would cancel out. Although this decision makes sense at
one level, medication interaction studies have not yet been
conducted to assess the validity of this assumption. Fourth,
investigators had to be aware that medications may be
prescribed to participants on the basis of underlying factors,
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such as a tendency to exhibit particular symptom clusters (e.g.
Swann et al., 2002). These underlying factors may affect both
sleep architecture and the participants medication regimen. In
order to assess this possibility, it may be useful to obtain a
more detailed illness history or obtain permission to contact
the prescribing physician in order to discuss the physicians
reasons for prescribing the medications taken by participants.
Finally, the effects of medications on sleep architecture are
undoubtedly quite complex, and include effects other than
increasing and decreasing sleep stages. For example, benzodi-
azepine receptor agonists may increase EEG beta activity while
decreasing delta and theta activity (Bastien et al., 2003). While
we recognize the limitations of our approach to medications,
we aimed to begin a process of developing a method for
dealing with pharmacological treatments that would allow for
the study of a diverse and representative sample of individuals
diagnosed with BD. We hope that future investigations will
further elaborate on our approach, utilizing lessons learned
about the issues discussed above.
Several limitations need to be considered. First, the sample
size was relatively small and largely composed of female
participants. Replication in larger and more diverse samples is
warranted. Second, we did not correct for multiple compar-
isons. While this increases the risk of Type I error, given that
this is a relatively new research area, we were also concerned
about decreasing the risk of Type II error (Nakagawa, 2004) so
as to maximize information gleaned from this initial study. The
small number of significant correlations in the control group is
noteworthy. On the basis of chance, if the results reflected false
positives, more significant findings had to have emerged in the
control group. Third, we acknowledge that the stages of
NREM sleep assessed are not entirely independent, and that
we cannot ascertain causal relationships between sleep stages
and subsequent symptoms and impairment. Fourth, we
utilized one night of PSG as our assessment of sleep architec-
ture. Future studies should assess sleep architecture over
multiple nights. Finally, the impact of co-morbid diagnoses
should be considered. In future studies, it may be useful to
include a comparison group with a diagnostic profile similar to
the co-morbid diagnoses in the BD group in order to ascertain
the impact of co-morbid disorders on sleep architecture.
Overall, our results point to sleep architecture as a potential
illness-maintaining mechanism in BD. Supporting the hypoth-
esis that the mood-regulatory role of REMmay malfunction in
mood disorders, REM activity was positively correlated with a
future increase in symptoms and impairment in our sample.
With respect to NREM sleep, we found that SWS activity was
also positively correlated with increased symptoms and
impairment. In contrast, our results suggest that Stage 2 sleep
may play a protective role in BD, as it was correlated with
decreased symptoms and impairment at follow-up. Indeed, it
may be the case that the ways in which REM and NREM
function in BD may be altered even in the inter-episode period,
such that sleep architecture characteristics are predictive of
future symptoms and impairment. Furthermore, by taking a
new approach to medication effects, we were able to assess
sleep in an inter-episode, representative, medicated BD sample
to demonstrate that medications do not have to be inherent
and intractable confounding factors in research of severe
psychopathology.
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